We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test for Protein Biomarker Could Detect Pancreatic Cancer at Very Early Stage

By LabMedica International staff writers
Posted on 02 Dec 2022

Pancreatic cancer initially produces only diffuse symptoms and is therefore often detected so late that it is difficult to treat successfully. More...

As a result, the mortality rate for this form of cancer is very high. The only effective treatment at present is surgery. For it to be effective, the cancer must not have spread outside the pancreas. Finding ways to detect pancreatic cancer earlier would be an important step towards treating it before it is too late, and thus saving lives. Now, a new study has found that in some people diagnosed with pancreatic cancer, levels of a particular substance in their blood can be seen to start rising slowly as early as two years before the cancer was diagnosed. This raises the possibility for future research to find ways to detect the dreaded cancer earlier.

In the study, researchers at Umeå University (Umeå, Sweden) used the blood donated to the research by people in north of Sweden over several decades, and they are now showing that this is a research resource of a magnitude that has few equals in the world. There are already two known markers in the blood for pancreatic cancer, two proteins called CA19-9 and CEA, respectively. They are effective in monitoring the development of the cancer once it is established.

The researchers therefore systematically searched the biobank for people who later developed pancreatic cancer and measured markers in their blood that could show that the cancer was coming. What they found was that a small proportion of people who developed pancreatic cancer had slowly rising levels of the CA19-9 marker from two years before they were diagnosed with the cancer. However, the researchers were unable to find a marker that was sufficiently early to predict which healthy people were at risk of later developing the cancer. None of the markers they looked for was sensitive enough to be used for general population-level screening.

“The finding suggests that changes occur in the body even before symptoms of the disease make themselves known, said Daniel Öhlund,” Associate Professor at the Department of Radiation Sciences and one of the researchers behind the study.

“The study shows that with the right markers, it may be possible to detect pancreatic cancer earlier than we do today, and that would be very valuable,” added Malin Sund, Professor at the Department of Surgical and Perioperative Sciences, who led the work on the current study.

“There is potential for a blood test to detect pancreatic cancer at a very early stage, but that we need to find more sensitive markers for the disease than we currently have,” said James Mason, one of the study's lead authors.

Related Links:
Umeå University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Quantitative lmmunoassay Test Menu
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.